# Cerenome, Inc.: financial statements, quarterly

CNSY · Nasdaq · CIK 1095981 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cnsy.md) · [Financials](/companies/cnsy/financials.md) · [Filings](/companies/cnsy/filings.md) · [Insiders](/companies/cnsy/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cnsy/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [1.7](/filings/0000950170-25-079738.md) | [1.3](/filings/0000950170-25-108874.md) | [1.5](/filings/0001193125-25-258596.md) | [1.4 d](/filings/0001193125-26-104258.md) | [1.1](/filings/0001193125-26-226978.md) | [1.4](/filings/0001193125-26-352444.md) | [1.4](/filings/0001193125-25-258596.md) | [1.4 d](/filings/0001193125-26-104258.md) | [1.0](/filings/0001193125-26-226978.md) | [0.4](/filings/0001193125-26-352444.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [2.5](/filings/0000950170-24-127014.md) | [2.8 d](/filings/0000950170-25-047698.md) | [2.8](/filings/0000950170-25-079738.md) | [2.8](/filings/0000950170-25-108874.md) | [2.9](/filings/0001193125-25-258596.md) | [2.2 d](/filings/0001193125-26-104258.md) | [1.8](/filings/0001193125-26-226978.md) | [1.2](/filings/0001193125-26-352444.md) | [2.4](/filings/0001193125-25-258596.md) | [2.9 d](/filings/0001193125-26-104258.md) | [2.9](/filings/0001193125-26-226978.md) | [4.3](/filings/0001193125-26-352444.md) |
| Operating income | $m | [(3.3)](/filings/0000950170-24-127014.md) | [(3.9) d](/filings/0000950170-25-047698.md) | [(3.3)](/filings/0000950170-25-079738.md) | [(3.7)](/filings/0000950170-25-108874.md) | [(3.8)](/filings/0001193125-25-258596.md) | [(3.9) d](/filings/0001193125-26-104258.md) | [(3.5)](/filings/0001193125-26-226978.md) | [(1.5)](/filings/0001193125-26-352444.md) | [(4.5)](/filings/0001193125-25-258596.md) | [(5.7) d](/filings/0001193125-26-104258.md) | [(7.1)](/filings/0001193125-26-226978.md) | [(9.1)](/filings/0001193125-26-352444.md) |
| Interest expense | $m | [0.1](/filings/0000950170-23-056844.md) | [0.1 d](/filings/0000950170-24-025851.md) | [0.0](/filings/0000950170-24-060395.md) | [0.0](/filings/0000950170-24-097091.md) | [0.1](/filings/0001193125-25-258596.md) | [0.1 d](/filings/0001193125-26-104258.md) | [0.5](/filings/0001193125-26-226978.md) | [0.0 d](/filings/0001193125-26-352444.md) | [0.0 d](/filings/0001193125-25-258596.md) | [0.0 d](/filings/0001193125-26-104258.md) | [0.0](/filings/0001193125-26-226978.md) | [0.0](/filings/0001193125-26-352444.md) |
| Net income | $m | [(3.2)](/filings/0000950170-24-127014.md) | [(3.8) d](/filings/0000950170-25-047698.md) | [(3.3)](/filings/0001193125-25-258596.md) | [(2.9)](/filings/0001193125-25-258596.md) | [(2.9)](/filings/0001193125-25-258596.md) | [(3.9) d](/filings/0001193125-26-104258.md) | [(17.4)](/filings/0001193125-26-352444.md) | [5.2](/filings/0001193125-26-352444.md) | [(4.4)](/filings/0001193125-25-258596.md) | [(5.7) d](/filings/0001193125-26-104258.md) | [(6.9)](/filings/0001193125-26-352444.md) | [(9.0)](/filings/0001193125-26-352444.md) |
| Diluted EPS | $ per share | [(1.00)](/filings/0000950170-24-127014.md) | not reported | [(0.75)](/filings/0000950170-25-079738.md) | [(0.71)](/filings/0000950170-25-108874.md) | [(0.37)](/filings/0001193125-25-258596.md) | not reported | [(29.86)](/filings/0001193125-26-226978.md) | [(0.16)](/filings/0001193125-26-352444.md) | [(0.04)](/filings/0001193125-25-258596.md) | not reported | [(1.05)](/filings/0001193125-26-226978.md) | [(1.31)](/filings/0001193125-26-352444.md) |
| Basic EPS | $ per share | [(1.00)](/filings/0000950170-24-127014.md) | not reported | [(0.75)](/filings/0000950170-25-079738.md) | [(0.45)](/filings/0000950170-25-108874.md) | [(0.37)](/filings/0001193125-25-258596.md) | not reported | [(29.86)](/filings/0001193125-26-226978.md) | [0.62](/filings/0001193125-26-352444.md) | [(0.04)](/filings/0001193125-25-258596.md) | not reported | [(1.05)](/filings/0001193125-26-226978.md) | [(1.31)](/filings/0001193125-26-352444.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [11.0](/filings/0000950170-23-056844.md) | [8.6](/filings/0000950170-25-047698.md) | [2.9](/filings/0000950170-24-060395.md) | [4.9](/filings/0000950170-24-097091.md) | [1.2](/filings/0000950170-24-127014.md) | [0.1](/filings/0001193125-26-104258.md) | [9.9](/filings/0000950170-25-079738.md) | [2.2](/filings/0000950170-25-108874.md) | [13.3](/filings/0001193125-25-258596.md) | [4.3](/filings/0001193125-26-352444.md) | [3.0](/filings/0001193125-26-226978.md) | [2.4](/filings/0001193125-26-352444.md) |
| Current assets | $m | [11.6](/filings/0000950170-23-056844.md) | [9.8](/filings/0000950170-25-047698.md) | [4.2](/filings/0000950170-24-060395.md) | [9.4](/filings/0000950170-24-097091.md) | [5.4](/filings/0000950170-24-127014.md) | [5.3](/filings/0001193125-26-104258.md) | [10.9](/filings/0000950170-25-079738.md) | [9.2](/filings/0000950170-25-108874.md) | [17.6](/filings/0001193125-25-258596.md) | [15.2](/filings/0001193125-26-352444.md) | [18.0](/filings/0001193125-26-226978.md) | [11.8](/filings/0001193125-26-352444.md) |
| Total assets | $m | [13.3](/filings/0000950170-23-056844.md) | [11.4](/filings/0000950170-25-047698.md) | [5.6](/filings/0000950170-24-060395.md) | [11.2](/filings/0000950170-24-097091.md) | [7.0](/filings/0000950170-24-127014.md) | [6.6](/filings/0001193125-26-104258.md) | [12.1](/filings/0000950170-25-079738.md) | [10.4](/filings/0000950170-25-108874.md) | [18.7](/filings/0001193125-25-258596.md) | [16.3](/filings/0001193125-26-352444.md) | [19.9](/filings/0001193125-26-226978.md) | [14.0](/filings/0001193125-26-352444.md) |
| Current liabilities | $m | [10.5](/filings/0000950170-23-056844.md) | [10.7](/filings/0000950170-25-047698.md) | [10.4](/filings/0000950170-24-060395.md) | [18.8](/filings/0000950170-24-097091.md) | [12.1](/filings/0000950170-24-127014.md) | [15.6](/filings/0001193125-26-104258.md) | [10.6](/filings/0000950170-25-079738.md) | [7.3](/filings/0000950170-25-108874.md) | [13.6](/filings/0001193125-25-258596.md) | [12.3](/filings/0001193125-26-352444.md) | [8.0](/filings/0001193125-26-226978.md) | [8.6](/filings/0001193125-26-352444.md) |
| Total liabilities | $m | [10.7](/filings/0000950170-23-056844.md) | [12.7](/filings/0000950170-25-047698.md) | [10.5](/filings/0000950170-24-060395.md) | [18.8](/filings/0000950170-24-097091.md) | [12.2](/filings/0000950170-24-127014.md) | [15.6](/filings/0001193125-26-104258.md) | [35.7](/filings/0000950170-25-079738.md) | [7.3](/filings/0000950170-25-108874.md) | [13.6](/filings/0001193125-25-258596.md) | [12.3](/filings/0001193125-26-352444.md) | [8.0](/filings/0001193125-26-226978.md) | [8.6](/filings/0001193125-26-352444.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [4.3](/filings/0000950170-23-056844.md) | [4.0](/filings/0000950170-25-047698.md) | [3.6](/filings/0000950170-24-060395.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [2.6](/filings/0000950170-24-127014.md) | [(1.3)](/filings/0001193125-26-104258.md) | [(4.8)](/filings/0001193125-25-258596.md) | [(7.6)](/filings/0001193125-25-258596.md) | [(5.2)](/filings/0001193125-25-258596.md) | [(8.9)](/filings/0001193125-26-352444.md) | [(23.6)](/filings/0001193125-26-352444.md) | [3.0](/filings/0001193125-26-352444.md) | [5.1](/filings/0001193125-25-258596.md) | [4.0](/filings/0001193125-26-352444.md) | [12.0](/filings/0001193125-26-352444.md) | [5.5](/filings/0001193125-26-352444.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,399) d](/filings/0000950170-24-127014.md) | [(1,881) d](/filings/0000950170-25-047698.md) | [(4,513)](/filings/0000950170-25-079738.md) | [(1,150) d](/filings/0000950170-25-108874.md) | [(3,680) d](/filings/0001193125-25-258596.md) | [(1,211) d](/filings/0001193125-26-104258.md) | [(6,172)](/filings/0001193125-26-226978.md) | [(5,798) d](/filings/0001193125-26-352444.md) | [(2,548) d](/filings/0001193125-25-258596.md) | [(6,257) d](/filings/0001193125-26-104258.md) | [(6,238)](/filings/0001193125-26-226978.md) | [(7,132) d](/filings/0001193125-26-352444.md) |
| Capital expenditure | $k | [10.0 d](/filings/0000950170-24-127014.md) | [42.0 d](/filings/0000950170-25-047698.md) | [40.0](/filings/0000950170-25-079738.md) | [81.0 d](/filings/0000950170-25-108874.md) | [14.0 d](/filings/0001193125-25-258596.md) | [11.0 d](/filings/0001193125-26-104258.md) | [3.0](/filings/0001193125-26-226978.md) | [7.0 d](/filings/0001193125-26-352444.md) | [27.0 d](/filings/0001193125-25-258596.md) | [30.0 d](/filings/0001193125-26-104258.md) | [818](/filings/0001193125-26-226978.md) | [499 d](/filings/0001193125-26-352444.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.8](/filings/0000950170-23-056844.md) | [2.3](/filings/0000950170-24-060395.md) | [2.5](/filings/0000950170-24-097091.md) | [3.2](/filings/0000950170-24-127014.md) | [4.3](/filings/0000950170-25-079738.md) | [10.7](/filings/0000950170-25-108874.md) | [7.9](/filings/0001193125-25-258596.md) | [0.6](/filings/0001193125-26-226978.md) | [8.4](/filings/0001193125-26-352444.md) | [107](/filings/0001193125-25-258596.md) | [6.6](/filings/0001193125-26-226978.md) | [6.9](/filings/0001193125-26-352444.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 7,589,625 at 2026-08-05, from the cover of the [10-Q filed 2026-08-14](/filings/0001193125-26-352444.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.